Differential expression of vascular endothelial growth factor A, its receptors VEGFR-1,-2, and-3 and co-receptors neuropilin-1 and-2 does not predict bevacizumab response in human astrocytomas

Neuro-Oncology

Volumn 18, Issue 2, 2016, Pages 173-183

  Baumgarten, Peter ^a   Blank, Anna Eva ^a   Franz, Kea ^a   Hattingen, Elke ^a,e   Dunst, Maika ^a   Zeiner, Pia ^a   Hoffmann, Katharina ^a   Bähr, Oliver ^a,c   Mäder, Lisa ^a   Goeppert, Benjamin ^d   MacHein, Marcia ^b   Seifert, Volker ^a   Steinbach, Joachim P ^a,c   Plate, Karl H ^a,c   Harter, Patrick N ^a,c   Mittelbronn, Michel ^a,c  

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

antiangiogenic therapy; bevacizumab; glioma; VEGF; VEGF receptors

Indexed keywords

BEVACIZUMAB; NEUROPILIN 1; NEUROPILIN 2; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3; ANGIOGENESIS INHIBITOR; NEUROPILIN-2, HUMAN; TUMOR MARKER; VASCULOTROPIN RECEPTOR; VEGFA PROTEIN, HUMAN;

ADOLESCENT; ADULT; AGED; ARTICLE; ASTROCYTOMA; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER SURVIVAL; CHILD; CONTROLLED STUDY; DRUG EFFECT; DRUG RESPONSE; FEMALE; HUMAN; HUMAN TISSUE; IN SITU HYBRIDIZATION; INFANT; MAJOR CLINICAL STUDY; MALE; NEWBORN; PREDICTION; PROTEIN EXPRESSION; ANTAGONISTS AND INHIBITORS; BRAIN NEOPLASMS; CANCER STAGING; ENZYME IMMUNOASSAY; FOLLOW UP; METABOLISM; MIDDLE AGED; PATHOLOGY; PRESCHOOL CHILD; PROGNOSIS; SURVIVAL RATE; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ASTROCYTOMA; BEVACIZUMAB; BIOMARKERS, TUMOR; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; NEUROPILIN-1; NEUROPILIN-2; PROGNOSIS; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SURVIVAL RATE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3; YOUNG ADULT;

EID: 84960346741     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nov288     Document Type: Article

References (48)

1. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114(2):97-109.
2. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-996.
3. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285(21):1182-1186.
4. Kim K, Li B,Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature. 1993;363(6423):841-844.
5. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science. 1983;219(4587):983-985.
6. Keck PJ, Hauser SD, Krivi G, et al. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science. 1989; 246(4935):1309-1312.
7. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 1989;246(4935):1306-1309.
8. Plate KH, Breier G,Weich HA, RisauW. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature. 1992;356(6398):133-135.
9. Plate KH, Breier G, Weich HA, Mennel HD, Risau W. Vascular endothelial growth factor and glioma angiogenesis: coordinate induction of VEGF receptors, distribution of VEGF protein and possible in vivo regulatory mechanisms. Int J Cancer. 1994; 59(4):520-529.
10. Wilting J, Christ B, Weich HA. The effects of growth factors on the day 13 chorioallantoic membrane (CAM): a study of VEGF165 and PDGF-BB. Anat Embryol (Berl). 1992;186(3):251-257.
11. Ryan HE, Lo J, Johnson RS. HIF-1 alpha is required for solid tumor formation and embryonic vascularization. EMBO J. 1998;17(11): 3005-3015.
12. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature. 1992;356(6398):133-135.
13. Ferrara N, Gerber H-P, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9(6):669-676.
14. Koch S, Tugues S, Li X, Gualandi L, Claesson-Welsh L. Signal transduction by vascular endothelial growth factor receptors. Biochem J. 2011;437(2):169-183.
15. Joukov V, Pajusola K, Kaipainen A, et al. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J. 1996;15(2):290-298.
16. Achen MG, Jeltsch M, Kukk E, et al. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci USA. 1998;95(2):548-553.
17. Shibuya M, Claesson-Welsh L. Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp Cell Res. 2006;312(5):549-560.
18. Kawasaki T, Kitsukawa T, Bekku Y, et al. A requirement for neuropilin-1 in embryonic vessel formation. Development. 1999; 126(21):4895-4902.
19. Soker S, Takashima S, Miao HQ, Neufeld G, Klagsbrun M. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell. 1998;92(6):735-745.
20. Favier B, Alam A, Barron P, et al. Neuropilin-2 interacts with VEGFR-2 and VEGFR-3 and promotes human endothelial cell survival and migration. Blood. 2006;108(4):1243-1250.
21. Murga M, Fernandez-Capetillo O, Tosato G. Neuropilin-1 regulates attachment in human endothelial cells independently of vascular endothelial growth factor receptor-2. Blood. 2005;105(5): 1992-1999.
22. Pan Q, Chathery Y, Wu Y, et al. Neuropilin-1 binds to VEGF121 and regulates endothelial cell migration and sprouting. J Biol Chem. 2007;282(33):24049-24056.
23. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350(23):2335-2342.
24. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355(24):2542-2550.
25. Vredenburgh JJ, Desjardins A, Herndon JE, et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res. 2007;13(4):1253-1259.
26. Taal W, Oosterkamp HM, Walenkamp AME, et al. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): A randomised controlled phase 2 trial. Lancet Oncol. 2014; 15(9):943-953.
27. Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med. 2014;370(8):709-722.
28. Baumgarten P, Harter PN, Tönjes M, et al. Loss of FUBP1 expression in gliomas predicts FUBP1 mutation and is associated with oligodendroglial differentiation, IDH1 mutation and 1p/19q loss of heterozygosity. Neuropathol Appl Neurobiol. 2014;40(2): 205-216.
29. Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: Response assessment in neuro-oncology working group. J Clin Oncol. 2010;28(11): 1963-1972.
30. Pope WB, Sayre J, Perlina A, Villablanca JP, Mischel PS, Cloughesy TF. MR imaging correlates of survival in patients with high-grade gliomas. AJNR Am J Neuroradiol. 2005;26(10):2466-2474.
31. Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008; 321(5897):1807-1812.
32. Chan AS, Leung SY,WongMP, et al. Expression of vascular endothelial growth factor and its receptors in the anaplastic progression of astrocytoma, oligodendroglioma, and ependymoma. Am J Surg Pathol. 1998;22(7):816-826.
33. Gerber HP, Condorelli F, Park J, Ferrara N. Differential transcriptional regulation of the two vascular endothelial growth factor receptor genes. Flt-1, but not Flk-1/KDR, is up-regulated by hypoxia. J Biol Chem. 1997;272(38):23659-23667.
34. Beck H, Acker T, Puschel AW, Fujisawa H, Carmeliet P, Plate KH. Cell type-specific expression of neuropilins in an MCA-occlusion model in mice suggests a potential role in post-ischemic brain remodeling. J Neuropathol Exp Neurol. 2002;61(4):339-350.
35. Zhang ZG, TsangW, Zhang L, Powers C, Chopp M. Up-regulation of neuropilin-1 in neovasculature after focal cerebral ischemia in the adult rat. J Cereb Blood Flow Metab. 2001;21(5):541-549.
36. Ulyatt C, Walker J, Ponnambalam S. Hypoxia differentially regulates VEGFR1 and VEGFR2 levels and alters intracellular signaling and cell migration in endothelial cells. Biochem Biophys Res Commun. 2011;404(3):774-779.
37. Xu Y, Yuan L, Mak J, et al. Neuropilin-2 mediates VEGF-C-induced lymphatic sprouting together with VEGFR3. J Cell Biol. 2010; 188(1):115-130.
38. Epis MR, Giles KM, Candy PA, et al. miR-331-3p regulates expression of neuropilin-2 in glioblastoma. J Neurooncol. 2014; 116(1):67-75.
39. Pan Q, Chanthery Y, Liang W-C, et al. Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth. Cancer Cell. 2007;11(1):53-67.
40. Tirand L, Frochot C, Vanderesse R, et al. A peptide competing with VEGF165 binding on neuropilin-1 mediates targeting of a chlorin-type photosensitizer and potentiates its photodynamic activity in human endothelial cells. J Control Release. 2006; 111(1-2):153-164.
41. Puputti M, Tynninen O, PernilaP, et al. Expression of KIT receptor tyrosine kinase in endothelial cells of juvenile brain tumors. Brain Pathol. 2010;20(21):763-770.
42. Ilhan A, Gartner W, Neziri D, et al. Angiogenic factors in plasma of brain tumour patients. Anticancer Res. 2009;29(2):731-736.
43. Brem SS, Bierman PJ, Brem H, et al. Central nervous system cancers. J Natl Compr Canc Netw. 2011;9(4):352-400.
44. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27(28):4733-4740.
45. Chauffer B, Feuvret L, Bonnetain F, et al. Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared with temozolomide-chemoradiation for unresectable glioblastoma: Final results of the TEMAVIR study from ANOCEF. Ann Oncol. 2014;25(7):1442-1447.
46. Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014;370(8):699-708.
47. Mathieu J, Zhang Z, Zhou W, et al. HIF induces human embryonic stem cell markers in cancer cells. Cancer Res. 2011;71(13): 4640-4652.
48. Piao Y, Liang J, Holmes L, et al. Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype. Neuro Oncol. 2012;14(11):1379-1392.